Compare FirstEnergy Corp. (FE) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs GSK plc — how do they compare? FirstEnergy Corp. trades at $44.85 (market cap $25.95B), while GSK plc trades at $46.59 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.5× FirstEnergy Corp.'s market cap, and FirstEnergy Corp. pays the higher dividend (4.15%). Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 71 Days and GSK plc for 93 Days on average.
| FE | GSK | |
|---|---|---|
Market Cap | $25.95B | $91.88B |
Volume | 5,643,833 | 7,730,529 |
Sector | Utilities | Health |
52-Week High | $51.91 | $61.18 |
52-Week Low | $43.04 | $43.24 |
Typical Hold Time | 71 Days | 93 Days |
Enterprise Value | $54.87B | $111.88B |
Dividend Yield | 4.15% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $44.58, up 0.72% with a bullish technical signal despite mixed earnings. The utility shows steady revenue growth to $15.09B in 2025 and maintains a 6.86% net margin, though recent quarters saw two EPS misses. Analyst consensus is Moderate Buy with a $52.80 target, while institutional interest grows with recent purchases by Nykredit and Corient Private Wealth.
FE offers stable utility operations with dividend support, but faces execution risks from its $36B Energize365 plan and rising debt. The stock's 8.4% upside to target and 4.2% dividend yield appeal to income investors, though high RSI suggests near-term pressure. Regulatory approvals and data-center demand are key catalysts.
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
